Just co-authored: Retinal oximetry may further the understanding of common vascular and ischemic disorders, including glaucoma, diabetic retinopathy, vein occlusions… Retinal oximetry in glaucoma: investigations and findings reviewed https://t.co/HQFJg48dAC Source by Thomas Ciulla, MD, MBA Return to main website.
Fauci on remdesivir for COVID-19: ‘This will be the standard of care’ https://t.co/iNKIdA4zS7 Source by Thomas Ciulla, MD, MBA Return to main website.
Proud of my team members Viral Kansara, PhD and Leroy Muya, PhD who were asked to present on Suprachoroidal Delivery at an upcoming conference “Gene Therapy for Ophthalmic Disorders”, in Boston, August 5 & 6:
https://t.co/fPipiEfIfb
Source by Thomas Ciulla, MD, MBA
Risks of turning to homemade cleaning products amid COVID-19 https://t.co/KM0I7018BA Source by Thomas Ciulla, MD, MBA Return to main website.
RT @ophthopedia: Ophthopedia Update: Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Pha… Source by Thomas Ciulla, MD, MBA Return to main website.
RT @ophthopedia: Ophthopedia Update: Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analys…
Source by Thomas Ciulla, MD, MBA
Just published….Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases… https://t.co/f25J5fPLea Source by Thomas Ciulla, MD, MBA Return to main website.
Just published… Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular edema: a real-world analysis of 28 658 patient eyes
Just published…This first FDA-approved gene therapy for a hereditary genetic disease, marks a new cycle of therapeutic innovation, especially for inherited retinal disease & potentially for common disorders, such as AMD & diabetic retinopathy.
Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development
Just published this article on cost effectiveness analysis… Cost Effectiveness Analysis in Retina. New Onetime Treatments Require New Reimbursement Models